white papers

How CDMOs Can Support Nanoparticles for Gene Therapy, Immuno-Oncology and Vaccines

Nanoparticles have experienced increasing demand in recent years in biopharmaceutical formulations, owing to their utility for both enhancing the characteristics of drugs and acting as drug delivery systems.

At present, a majority of CDMOs outsource their nanoparticle supply chain, however in house manufacturing of nanoparticles at CDMOs is anticipated to create new market opportunities aligning to biopharma's needs for these molecules.

Download our white paper to learn how partnering with a CDMO experienced in nanoparticle formulation and scale-up can help identify and overcome challenges to maximize the potential for a drug programs success.

Streamlining Your Process Development Journey to GMP Manufacturing

Many CDMOs specialize in certain parts of the drug development lifecycle. Meanwhile, integrated turn-key offerings that support...


Finding the Right CDMO Partner for Tech Transfer

Regardless of where a drug candidate is in the development pipeline, performing a technology transfer (tech transfer) presents...


Using Viruses to Target Cancer Cells

Innovation in cancer therapeutics is moving at an accelerated pace. Advancements in the development and manufacturing of...